Dashboard
1
Weak Long Term Fundamental Strength with a -161.75% CAGR growth in Operating Profits over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 3.61
- The company has been able to generate a Return on Equity (avg) of 6.23% signifying low profitability per unit of shareholders funds
2
Negative results in Jun 25
3
Risky -
4
Below par performance in long term as well as near term
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0.81%
0%
0.81%
6 Months
16.71%
0%
16.71%
1 Year
-10.63%
0%
-10.63%
2 Years
49.94%
0%
49.94%
3 Years
6.35%
0%
6.35%
4 Years
-80.66%
0%
-80.66%
5 Years
0%
0%
0.0%
PolyPeptide Group AG for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
4.34%
EBIT Growth (5y)
-161.75%
EBIT to Interest (avg)
3.61
Debt to EBITDA (avg)
0.18
Net Debt to Equity (avg)
0.02
Sales to Capital Employed (avg)
0.74
Tax Ratio
7.63%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
8.85%
ROE (avg)
6.23%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.53
EV to EBIT
-82.26
EV to EBITDA
33.21
EV to Capital Employed
2.50
EV to Sales
2.27
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-3.04%
ROE (Latest)
-10.58%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bearish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
311.30
282.00
10.39%
Operating Profit (PBDIT) excl Other Income
-10.20
36.30
-128.10%
Interest
7.20
3.40
111.76%
Exceptional Items
-2.60
0.00
Consolidate Net Profit
-50.00
7.80
-741.03%
Operating Profit Margin (Excl OI)
-119.30%
36.00%
-15.53%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is 10.39% vs -7.51% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is -741.03% vs -84.74% in Dec 2022
About PolyPeptide Group AG 
PolyPeptide Group AG
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






